Segment Disclosure

12 Months Ended

Jun. 30, 2017

Segment Disclosure

Segment Disclosure

15. Segment Disclosure

        The Company has one operating and reporting segment (oncology systems group), which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients. The Company's Chief Executive Officer, its Chief Operating Decision Maker, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The Company does not assess the performance of its individual product lines on measures of profit or loss, or asset based metrics. Therefore, the information below is presented only for revenues and long-lived tangible assets by geographic areas.

        Revenues attributed to a country or region is based on the shipping addresses of the Company's customers. The following summarizes revenue by geographic region (in thousands):

	Years ended June 30,
	2017		2016		2015
Americas	$	151,442	$	159,517	$	174,000
Europe, Middle East, India and Africa		104,026		138,877		110,534
Asia Pacific		59,278		62,888		57,618
Japan		68,668		37,518		37,649
Total	$	383,414	$	398,800	$	379,801

        Information regarding geographic areas in which the Company has long-lived tangible assets is as follows (in thousands):

	June 30, 2017		June 30, 2016
Americas	$	18,435	$	23,842
Europe, Middle East, India and Africa		730		551
Asia Pacific (excluding Japan and India)		1,533		1,342
Japan		2,364		2,143
Total	$	23,062	$	27,878